JTO: Phase 3 randomized trial of SCLC preventive brain irradiation with or without hippocampal protection

According to the stage and characteristics of the disease, the incidence of brain metastases (BM) in patients with small cell lung cancer is very high, exceeding 50%.

At present, several studies have proposed several interaction mechanisms to explain neurocognitive decline, including vascular disease, oligodendrocyte reduction, central nervous system inflammation, and ecological degradation of progenitor cells in the hippocampus, which is a learning and The important structure of memory.

Modern radiotherapy techniques, such as intensity modulated conformal radiotherapy and volumetric arc intensity modulated radiotherapy, allow the entire brain to be treated with standard radiation doses while maintaining low-dose exposure to the hippocampus.

In this study, patients with small cell lung cancer were randomly divided into 2 groups and received standard PCI or HA-PCI treatment at a dose of 2.

Table 1 Treatment plan for all patients receiving HA-PCI treatment

From April 2013 to March 2018, a total of 168 patients were randomly enrolled in this study.

There were no significant differences between the two groups in performance on other cognitive tests such as tests of memory, executive function, attention, motor function, and processing speed.

In summary, the results of this study show that compared with traditional PCI, the probability of neurocognitive decline in patients with small cell lung cancer receiving HA-PCI has not been found to be reduced.

Belderbos, José SA et al.